These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7554993)

  • 1. Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis.
    Miyata T; Wada Y; Maeda K
    Contrib Nephrol; 1995; 112():52-64. PubMed ID: 7554993
    [No Abstract]   [Full Text] [Related]  

  • 2. New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction.
    Miyata T; Maeda K
    Nephrol Dial Transplant; 1996; 11 Suppl 2():140-3. PubMed ID: 8804015
    [No Abstract]   [Full Text] [Related]  

  • 3. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis.
    Miyata T; Sprague SM
    Nephrol Dial Transplant; 1996; 11 Suppl 3():86-90. PubMed ID: 8840320
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathogenesis of dialysis-related amyloidosis.
    Miyata T; Maeda K
    Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):493-7. PubMed ID: 8591057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis.
    Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF
    Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum.
    Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y
    Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of advanced glycation end-products in renal failure.
    Miyata T; Iida Y; Horie K; Cai Z; Sugiyama S; Maeda K
    Nephrol Dial Transplant; 1996; 11 Suppl 5():27-30. PubMed ID: 9044303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
    Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y
    Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular heterogeneity of amyloid beta2-microglobulin and modification with advanced glycation end products.
    Mironova R; Niwa T
    J Chromatogr B Biomed Sci Appl; 2001 Jul; 758(1):109-15. PubMed ID: 11482729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-2 microglobulin in ESRD: an in-depth review.
    Winchester JF; Salsberg JA; Levin NW
    Adv Ren Replace Ther; 2003 Oct; 10(4):279-309. PubMed ID: 14681859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure.
    Miyata T
    Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta2-Microglobulin dialysis amyloid and its formation: role of 3-deoxyglucosone and advanced glycation end products.
    Niwa T
    Nephron; 1997; 76(4):373-91. PubMed ID: 9274834
    [No Abstract]   [Full Text] [Related]  

  • 13. Implication of the glycoxidation and lipoxidation reactions in the pathogenesis of dialysis-related amyloidosis (Review).
    Sugiyama S; Miyata T; Inagi R; Kurokawa K
    Int J Mol Med; 1998 Nov; 2(5):561-5. PubMed ID: 9858652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis.
    Iida Y; Miyata T; Inagi R; Sugiyama S; Maeda K
    Biochem Biophys Res Commun; 1994 Jun; 201(3):1235-41. PubMed ID: 8024566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid, advanced glycation end products, and dialysis related arthropathy.
    McDonald SP; Coates PT; Disney AP
    Ann Rheum Dis; 1998 Apr; 57(4):193-5. PubMed ID: 9709172
    [No Abstract]   [Full Text] [Related]  

  • 16. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products.
    Miyata T; Iida Y; Ueda Y; Shinzato T; Seo H; Monnier VM; Maeda K; Wada Y
    Kidney Int; 1996 Feb; 49(2):538-50. PubMed ID: 8821842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Carbonyl stress' and dialysis-related amyloidosis.
    Miyata T; Ueda Y; Saito A; Kurokawa K
    Nephrol Dial Transplant; 2000; 15 Suppl 1():25-8. PubMed ID: 10737163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis.
    Miyata T; Inagi R; Kurokawa K
    Miner Electrolyte Metab; 1999; 25(1-2):114-7. PubMed ID: 10207272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.
    Miyata T; Inagi R; Iida Y; Sato M; Yamada N; Oda O; Maeda K; Seo H
    J Clin Invest; 1994 Feb; 93(2):521-8. PubMed ID: 8113390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Amyloidosis in patients undergoing long-term hemodialysis: elucidation of etiological mechanism and therapeutic stratigy].
    Shimojyo F
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():56-60. PubMed ID: 15796057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.